One-third of the human population has hypertension. In the USA, despite the fact that 75% of individuals use antihypertensive medication, in only 53% (~41 million) of those taking such medication is blood pressure controlled 1 . This low rate of control might, in part, reflect a serious problem with drug adherence, owing to the asymptomatic nature of hypertension and the poorly tolerated side effects of current medications. Substantial savings in healthcare costs would result if an individual's blood pressure could be reduced to <140/90 mmHg 2 . In adults over 40 years of age, there is clear evidence that a 10-mmHg rise in diastolic blood pressure (DBP) above normal levels (80 mmHg) doubles the risk of death from cardiovascular disease 3 . Furthermore, at least 8% of an estimated 900 million people with hypertension worldwide 4 have developed and currently experience drug resistance 5, 6 . Categorically, there remains an unmet clinical need for ways to control blood pressure.
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The most recently introduced antihypertensive drug is aliskiren, a renin inhibitor released in 2007. This was the first new drug to emerge for hypertension in 13 years, yet its efficacy beyond the existing reninangiotensin-aldosterone enzyme inhibitors and receptor blockers is questionable, and associated adverse effects call into question its long-term benefit-harm relationship 7 . The paucity of new pharmacological antihypertensive agents has led to a series of device-based interventional studies, including renal denervation 8 , stimulation of carotid baroreceptors 9 , deep brain stimulation 10 and arterial venous anastomosis 11, 12 . Here we introduce a new mechanistic approach that uses a highly selective small-molecule antagonist, and we provide preclinical and clinical data to justify its use in a future clinical trial for hypertension.
Currently, the carotid body is under consideration as a therapeutic target for cardiovascular disease. The carotid body chemoreflexevoked sympathoexcitatory response is potentiated in both a preclinical model of hypertension-the spontaneously hypertensive (SH) rat-and in humans with hypertension [13] [14] [15] [16] [17] [18] , and denervation of the carotid body is evidently an effective way to control both the development and maintenance of high blood pressure in the SH rat 19, 20 . On the basis of these findings, we concluded that in conditions of hypertension, the carotid body chemoreceptors generate aberrant excitatory tone that drives up sympathetic activity and causes high blood pressure 14, 21 . Indeed, we found that when this carotid body tone is switched off through hyperoxia or nerve section to disconnect the carotid body from the brain, arterial pressure and sympathetic activity are reduced in SH rats, but are unaffected in a normotensive rat strain 14 . In humans with hypertension, hyperoxia lowers sympathetic activity 18 , and carotid body resection can reduce arterial pressure substantially 22 . Thus, these animal and human data support the presence of aberrant carotid body discharge as contributing to hypertension. Although the mechanistic basis for the carotid body aberrant tone is unknown, it could be pivotal for refining new pharmacological antihypertensive approaches, as we propose here.
A plethora of mechanisms governs carotid body signaling [23] [24] [25] [26] [27] . In our current investigation, we have studied the role of adenosine triphosphate (ATP)-gated ion channels (called purinergic P2X receptors), specifically the C-fiber-localized, P2X3-receptor subtypes, which are commonly associated with afferent sensitization and might contribute to hyperreflexic disease states in a variety of organs 28, 29 . ATP is one of a number of transmitters involved in hypoxic signaling in the carotid body [30] [31] [32] [33] [34] [35] . P2X3-receptor expression is present in both carotid bodies and petrosal ganglia neurons of normotensive rats 36 . Moreover, combined P2X2-and P2X3-subunit deletion in mice reduces the ventilatory response to hypoxia, as compared to wild types 37 . We hypothesized that the P2X3 receptor contributes to both peripheral chemo-hyperreflexia and aberrant discharge of the carotid body in hypertension, and that blockade of this receptor would cause an antihypertensive effect. To address this, we have tested the effects of highly selective P2X3-receptor antagonists on hypertension in rats and have demonstrated the applicability of these preclinical findings to humans with hypertension.
RESULTS

Hyperactivity of carotid bodies in hypertensive rats
We first tested whether the carotid body was more active in conditions of high blood pressure. We recorded carotid body afferent discharge from the carotid sinus nerve of the in situ preparation (an unanesthetized decerebrated rat on cardiopulmonary bypass). Sodium cyanide (NaCN), simulating hypoxia, was used to stimulate the peripheral chemoreflex response because this treatment provides a specific, quantifiable and temporally controlled stimulus that is repeatable over a course of hours. Both basal discharge and chemoreflex-evoked volleys (15-30 µg NaCN, intra-arterially (i.a.)) were elevated in rats with hypertension, as compared to those without hypertension (SH versus Wistar rats: basal, 24.9 ± 2 versus 1.4 ± 0.3 spikes/s, respectively, P < 0.001; chemoreflex, 62.3 ± 3 versus 28.3 ± 2 spikes/s, respectively; P < 0.001, Fig. 1a-c) . Next, we used a low dose of dopamine to inhibit carotid body discharge 38, 39 . In SH rats in vivo, dopamine infusion (10 µg/kg/min intravenously (i.v.), as described 39 ) depressed respiration, an effect not observed in Wistar rats (Fig. 1d) , which suggests the presence of carotid body tonicity in animals with hypertension. During intracellular recordings in the in situ preparation, neurons were characterized as responding to the NaCN stimulus, characterizing them as chemoreceptive primary afferent petrosal ganglion neurons. Such neurons, recorded from hypertensive rats, were more depolarized (−51.5 ± 0.9 versus −55.7 ± 1 mV; P < 0.001, Fig. 2a,c and Supplementary Fig. 1 ), exhibited tonic firing (1.5 ± 0.8 versus 0 Hz; Fig. 2a ) and displayed an enhanced chemoreflex-evoked firing response to an equivalent dose of NaCN (22.5 µg, 123 ± 5 versus 52 ± 3 spikes; P < 0.001, Fig. 2a,d) , as compared to normotensive rats. In sum, when compared to the normotensive rat, the carotid body of an SH rat is hyperactive, generating both aberrant tone and hyperreflexia.
Chemoreceptive petrosal neuron excitability in SH rats
We next compared the electrical excitability of chemoreceptive petrosal neurons in SH and Wistar rats. We found that the neurons recorded from SH rats, as compared to those from Wistar rats, exhibited enhanced excitability to injected current pulses; for example, a 1 nA current pulse evoked 25 ± 1.1 spikes in SH rats versus 15 ± 1.7 spikes in Wistar rats (Supplementary Fig. 2a ,b, n = 6; P < 0.05). Neither the membrane input resistance of these chemoreceptive petrosal neurons (119 ± 3 versus 117 ± 9 MΩ; Supplementary Fig. 1c) nor their whole-cell capacitance (Supplementary Fig. 1d ) was different between the rat strains.
P2X3-receptor antagonism normalizes chemoreceptive petrosal neuron excitability in SH rats Given that the P2X3 receptor is expressed in the carotid body of normotensive rats 36 and is associated with pathological afferent sensitization in numerous other organs 28, 29, 33 , we assessed whether this receptor is involved in carotid body dysfunction in SH rats in situ. In SH rats, focal delivery of a highly selective, noncompetitive P2X3-receptor antagonist (AF-353; 15 nl, 20 µM 40 ) via a glass micropipette inserted into the ipsilateral carotid body caused hyperpolarization (−9.9 ± 2.1 mV; n = 12, P < 0.001; Fig. 2b,c) and total abolition of ongoing activity (Fig. 2b) , as well as a reduction in the chemoreflex sensitivity of petrosal chemoreceptive neurons (from 123 ± 5 to 34 ± 2 spikes; n = 12, P < 0.001, Fig. 2b,d) . In normotensive animals in situ, AF-353 delivery also caused hyperpolarization (−4.4 ± 1.8 mV; n = 10, P < 0.001; Fig. 2c ) and reduced the chemoreflex-evoked volley (from 52 ± 3 to 32 ± 2 spikes; n = 10, P < 0.001; Fig. 2b,d ). The magnitudes of both the hyperpolarization and the reduction in chemoreflex-evoked spiking were greater in SH rats than in Wistar rats (P < 0.001; Fig. 2c,d) . Notably, during P2X3-receptor antagonism, carotid body activation yielded comparable firing responses in petrosal neurons between the rat strains (SH, 34 versus Wistar, 32 spikes; not significant (n.s.)); this effect of P2X3 antagonism was reversible in SH rats upon washout of the drug (Fig. 2b) . After AF-353 treatment, the intrinsic firing response to injected depolarizing current pulses was reduced in SH rat neurons (for example, at 1 nA, 25 ± 1 to 19 ± 1 spikes; P < 0.05; Supplementary Fig. 2a,b) , but not in Wistar rat neurons (15 ± 2 to 12 ± 2, n.s.).
P2X3 receptors are upregulated in petrosal neurons of SH rats
We next tested whether the expression of P2X3 receptors is upregulated in SH rat petrosal neurons. Single-cell PCR analysis of characterized chemoreceptive petrosal ganglion neurons recorded from SH rats in situ ( Fig. 2e ) revealed a greater than four-fold upregulation of P2x3 receptor mRNA relative to that in Wistar rats ( Fig. 2f ; n = 6, P < 0.001). A comparable upregulation of the P2X3 receptor at the protein level in carotid bodies was confirmed by western blot (Fig. 3a) . Notably, no difference in P2x3 or P2x2 mRNA expression in nonchemoreceptive petrosal neurons was observed between the rat strains ( Supplementary Fig. 2e ), which is indicative of specificity to chemoreflex neurons. Moreover, there were no differences between the rat strains in their expression of P2x2 (Fig. 2f) or tyrosine hydroxylase (a marker of glomus cells) mRNA expression in either petrosal chemoreceptive neurons ( Supplementary Fig. 2c ) or in chemoreceptive neurons located in the nucleus tractus solitarii ( Supplementary  Fig. 2f ). P2X3 receptors were observed in tyrosine-hydroxylasepositive glomus cells (Fig. 3b) , as well as in axons within the carotid body ( Supplementary Fig. 3a,b) .
SH rat chemoreceptive petrosal cells are sensitized to ATP
On the basis of the upregulation of P2X3 receptor expression in the chemoreceptive petrosal neurons of SH rats, we tested whether the sensitivity of these neurons to ATP differed between the rat strains. The application (15 nl) of ATP or α-β-methylene-ATP focally to the carotid body produced dose-dependent increases in the firing and membrane depolarization of petrosal neurons. Notably, petrosal neurons in the SH rat were more sensitive than those from Wistar rats; for ATP, EC 50 (half-maximal effective concentration) values were 8.8 ± 2.2 versus 17.2 ± 1.3 in SH versus Wistar rats, respectively (P < 0.001; Fig. 3c,d) , and for α-β-methylene-ATP, EC 50 values were 9.4 ± 2.1 versus 16.2 ± 2.4 in SH versus Wistar rats, respectively (P < 0.05; Supplementary  Fig. 4a ,b). Consistent with these findings, the P2X3-receptorsensitive inward current evoked by ATP in chemoreceptive petrosal neurons was greater in SH than in Wistar rats (P < 0.0001; Fig. 3e ,f).
Systemic blockade of P2X3 receptors is antihypertensive
Next, we tested whether antagonism of carotid body P2X3 receptors lowers arterial blood pressure in SH rats. 1-h infusions of a highly selective, noncompetitive P2X3-receptor antagonist called AF-219 were made at 1, 4 and 8 mg/kg/h, i.v. This compound was preferred for use in vivo over the structurally related, more lipophilic antagonist AF-353 because AF-219 has been used clinically for other indications in humans 29 and does not cross the blood-brain barrier. We performed a pharmacokinetic analysis to assess plasma concentrations of AF-219 in SH rats ( Fig. 4a and Supplementary Fig. 5 ), and subsequently found correlations between plasma drug concentrations, with falls in systolic blood pressure (SBP) (Fig. 4a) . In SH rats, basal arterial pressure was 151 ± 3/109 ± 3 (SBP/DBP) mmHg. AF-219 produced a dose-dependent drop in arterial pressure (Fig. 4a) ; no response was observed in Wistar rats ( Fig. 4b ; Supplementary  Fig. 6 ). At a dose of 8 mg/kg/h, SBP/DBP in SH rats fell by −28 ± 3/−26 ± 4 mmHg ( Fig. 4a ; n = 7, P < 0.001). Heart rate and respiratory frequency also decreased (by −38 ± 8 and −12 ± 3 beats and breaths/min, respectively; Supplementary Fig. 6 ; n = 7, P < 0.01). Notably, after carotid body resection in SH rats, a 30-min infusion of AF-219 (8 mg/kg/h) still caused a residual fall of −17 ± 3 mmHg in Fig. 4b ; n = 7, P < 0.05; Supplementary Fig. 7 ), which suggests P2X3-receptor-driven afferent activity of non-carotid body origin. The chemoreflex-evoked increase in arterial pressure in conscious SH rats was also reduced after systemic blockade of P2X3 receptors by AF-219 (bolus doses given i.v. >1 mg/kg; n = 4, P < 0.05; Fig. 4c ).
These data suggest that P2X3-receptor antagonism reduces aberrant afferent drive from the carotid body, thereby lowering blood pressure and normalizing its reflex sensitivity.
P2X3 receptor blockade reduces sympathetic tone in SH rats
To study the mechanisms by which P2X3-receptor blockade lowers arterial pressure in SH rats, we evaluated the effect of P2X3-receptor antagonism on cardiovascular autonomic activity. Ongoing basal levels of lumbar sympathetic nerve activity (SNA) recorded in situ were reduced from 20.8 ± 2.2 to 13.7 ± 2.5 µV ( Fig. 5a-c ; n = 12, P < 0.001) after focal delivery of AF-353 (15 nl, 20 µM) to carotid bodies bilaterally in SH rats. The SNA levels observed after AF-353 delivery were similar to those in normotensive rats either before (12.3 ± 2.6 µV) or after AF-353 application (11.7 ± 2.3 µV; Fig. 5c ; n = 12, n.s.). Chemoreflex-evoked increases in expiratory-modulated SNA were 209 ± 12% and 131 ± 11% for SH and Wistar rats, respectively. After AF-353 delivery to carotid bodies, these levels were reduced significantly, to 76 ± 11% and 69 ± 7.8% in SH and Wistar rats, respectively ( Fig. 5a-e ; n = 12, P < 0.001); after AF-353 delivery, these levels were not different between rat strains. After 20-30 min, the depressant effects of AF-353 on SNA (both basal and reflex-evoked) were reversed (Fig. 5b) indicating that the effects of AF-353 on ongoing lumbar chain sympathetic activity chemoreflex-evoked discharge were reversible. We replicated these data using 2′,3′-O-(2,4,6-trinitrophenyl) adenosine-5′-triphosphate tetra(triethylammonium) salt or TNP-ATP (f) Quantification of the AF-353-sensitive, ATP-evoked inward current in Wistar and SH rats. Neurophysiological data were from the in situ arterially perfused preparation, and comparisons were made using an unpaired t-test. All data are means ± s.e.m. *P < 0.05; ***P < 0.001. ( Supplementary Fig. 8 ), a high-affinity, nonselective P2X-receptor antagonist that is structurally distinct from AF-353 and that inhibits P2X1, P2X3 and heteromeric P2X2/P2X3, with a 1,000-fold selectivity over homomeric P2X2, P2X4 and P2X7 receptors. This evidence supports the concept that the antihypertensive effects of AF-353 are due to the blockade of P2X3 homomeric and P2X2/P2X3 heteromeric receptors, rather than to nonselective actions on ionic conductances and/or other receptors. Recordings were made from renal sympathetic nerves using radiotelemetry in conscious SH rats in vivo during chronic systemic P2X3-receptor antagonism using AF-219. This reduced both the basal renal sympathetic activity (−37 ± 13 normalized units relative to baseline; Fig. 5f ; P < 0.05), which followed a similar time course to the fall in SBP (Fig. 4a) , and the chemoreflex-evoked increase in renal sympathetic activity (Fig. 5g,h ; P < 0.05). Washout data (Fig. 5h) indicated a reversal of the drug-evoked reduction in the chemoreflex-evoked renal sympathetic nerve response. Spontaneous renal sympathetic baroreflex gain was enhanced after AF-219 (0.14 ± 0.07 versus 0.01 ± 0.02 %/mmHg; P < 0.05), but not vehicle, infusion. Although no changes in autonomic activity to the heart were detected in conscious SH rats after AF-219 infusion (Supplementary Fig. 9a,b) , spontaneous cardiac baroreflex was increased (0.13 ± 0.04 to 0.27 ± 0.05 ms/mmHg; Supplementary Fig. 9c ; P < 0.001). We next tested the translatability of the SH rat data and potential use of a P2X3-receptor antagonist for human hypertension.
P2X3-receptor expression and tonic drive in human carotid bodies
If P2X3 receptors within the carotid body are to be considered as an antihypertensive target in humans, then an essential first step is a demonstration of their presence in human carotid bodies. Carotid bodies were obtained from cadavers of individuals with a medical history of hypertension, and P2X3 expression was determined by both immunocytochemistry (n = 5) and western blot (n = 4). P2X3-receptor antibody specificity was determined by using a blocking peptide (Supplementary Fig. 10 ). P2X3-receptor expression was prevalent in these carotid bodies (Fig. 6a,b and Supplementary  Fig. 11a ) and showed co-expression with the glomus cell marker tyrosine hydroxylase (Fig. 6a) . Axons in the carotid body also expressed Fig. 11b ). This expression pattern was similar to that seen in SH rats (Fig. 3b) .
Having verified the presence of P2X3 receptors in carotid bodies of humans with hypertension, we next tested whether tonicity in the carotid body of humans with hypertension exists, as assessed using low-dose dopamine infusion (5 min; 2 µg/kg/min i.v.), which was described previously, to inactivate the carotid body 38 . In six individuals with hypertension, we observed a biphasic response in minute ventilation to dopamine infusion (Fig. 6c) , which comprised a depression during the infusion (−1.28 ± 0.52 l/min; P < 0.05), followed by an overshoot (relative to vehicle infusion) after the termination of dopamine infusion (1.28 ± 0.41 l/min; P < 0.05). These data indicate that the carotid body of humans with hypertension can generate tonic drive, and that dopamine infusion enables the identification of this aberrant discharge.
DISCUSSION
Many mechanisms that mediate reflex responses to hypoxia have been described in the carotid body that could contribute to its sensitization in disease states, including mechanisms involving two pore-domain potassium channels and acid-sensing ion channels 14, 25 , hydrogen sulfide 23, 24 , carbon monoxide 24 , nitric oxide 24 and carotid body blood flow 27 . However, studies in vitro have also shown a major role for ATP release from glomus cells in response to hypoxia in the rat 30 and the cat 31 , as well as in humans 35 . Whether there is a link between ATP release by these cells and any of the aforementioned mechanisms remains an open question. Moreover, P2X2-and P2X3-receptor subunits were both found to be present in the rat carotid body 36 , and, by using co-cultures of glomus and petrosal cells in vitro, Nurse and colleagues 36 demonstrated that ATP acts via P2X receptors to excite petrosal neurons. This evidence was based on the use of suramin, a weak and nonselective P2X antagonist. P2X2-containing channels (P2X2 homomeric and/or P2X3 homomeric) probably dominate the normal physiological ventilatory response to hypoxemia, given that both P2X2 single-knockout and P2X2 and P2X3 double-knockout mice, but not P2X3 single-knockout mice, show ventilatory hyporeflexia 37 . Thus, changes in P2X3-subunit expression seem to be associated with pathological sensitization of carotid body reflexes.
In the present study, by using selective antagonists, we found that both exogenous and endogenous ATP released from the carotid body can act on P2X3-subunit-containing receptors on petrosal neurons. A limitation to our study is that we cannot fully establish the relative contribution of homomeric P2X3 versus heteromeric P2X2/ P2X3 receptors in such responses. Although the antagonists that we used have a higher affinity for P2X3 homomeric than heteromeric P2X2/P2X3 receptors 28 , it seems reasonable that P2X3 homomeric receptor upregulation in the carotid body could account for increased ATP sensitivity, because this form of the channel in recombinant studies displays substantially lower EC 50 values than the homomeric receptor to the nucleotide 40 . In addition, the marked upregulation of P2x3 mRNA rather than P2x2 would probably precipitate a stoichiometric shift toward the expression of channels dominated by the P2X3 subunit. Data from voltage-clamp experiments indicate the presence of a nondesensitizing current to α-β-methyl-ATP recorded from chemoreceptive petrosal neurons and the probable involvement of P2X3 homomeric and P2X2/P2X3 heteromeric receptors.
Our data indicate that P2X3 receptors in the carotid body have a crucial role in controlling its reflex sensitivity in SH, but not in normotensive, rats. In SH rats, the upregulation of P2X3-receptor expression in the carotid body seems, in part, to be causal for the etiology of the tonicity, hyperreflexia of chemoreceptive petrosal neurons and downstream hyperactivity of the sympathetic nervous system. We acknowledge that chemoreceptive petrosal neurons could have a larger receptive field in the carotid body of SH, as compared to Wistar, rats, which could contribute to the hyperactive state of the petrosal neurons. Notably, upregulated P2x3 mRNA was exclusive to chemoreceptive petrosal neurons (i.e., it was not upregulated in nonchemoreceptive petrosal cells). The carotid body tonicity that we report from preparations in situ (1.5 Hz per petrosal neuron) most probably underestimates carotid body tonicity in conscious SH rats because the recordings were made under hyperoxic conditions, which are known to temper carotid body discharge 14, 20 . The hyperoxic conditions might also explain the dearth of activity in neurons recorded from Wistar rats. Whether P2X3-receptor upregulation alone, without the need for increased ATP release or reduced ATP clearance, is sufficient for pathological carotid body signaling in the SH rat is unclear. However, given that the microvasculature of the carotid body is hypertrophied in the SH rat 41 , and given the possibility that arterioles feeding the carotid body receive high sympathetic drive 41 , the tissue is likely to be hypoxic and hypercapnic, a condition that is known to induce ATP release 42 . Additionally, inflammation, which is known to be present in the carotid body of SH rats 41 , can also drive ATP release 43 .
The association of P2X3-receptor upregulation and aberrant afferent signaling has been previously observed 28 and is consistent with the sensitization of visceral sensing mechanisms from, for example, the bladder 44, 45 , urinary tract 46 , larynx 29 , lungs 47 , gastro-intestinal tract 48, 49 and skeletal muscle 50 in numerous disease states, including chronic pain 51 . Elucidation of the mechanisms that control P2X3-receptor expression at both the transcriptional and cytosolic trafficking levels in the carotid body and other organs now becomes an important issue to enable the translation of P2X3 as a new drug target into the clinical arena.
The finding that P2X3-receptor activation evokes a rapidly inactivating current in vitro 52 seems inconsistent with an ability of P2X3 receptors to maintain tonic drive from the carotid body (or any organ). Notably, low pH, a postulated condition in the carotid body of SH rats 41 , can potentiate P2X3-receptor inward currents and reduce desensitization 53 . Furthermore, the concept has been developed that P2X3-receptor activation might lead to local generator potentials and calcium transients in afferent terminals that lower the threshold for activation by any other excitatory agent, as described in somatosensory nociceptor C-fibers as leading to a condition of hyperalgesic priming 54, 55 . Such threshold attenuation and chemoceptive priming might be under the control of the P2X3 receptor in the carotid body, although we do not rule out a possible involvement of P2X2/P2X3 heteromeric receptors, given that these channels show less rapid desensitization 52 , which is consistent with our voltage-clamp data.
We found a robust dose-dependent lowering of arterial pressure after systemic administration of AF-219 to SH rats. AF-219 administration also led to a fall in blood pressure in rats with Goldblatt hypertension (W. Pijacka, F.M. McBryde & J.F.R. Paton, unpublished data), which indicates that the antihypertensive effect of P2X3 antagonism is not restricted to the SH rat. We propose that the effect of P2X3-receptor antagonism is primarily, but not exclusively, acting within the carotid body, given that the antagonist-induced fall in arterial pressure was reduced substantially, but not abolished, after carotid body ablation compared to intact rats. Further support for a direct action of AF-219 on the carotid body is that the fall in arterial pressure, which was accompanied by a reduction in sympathetic activity in vivo, was also observed after the direct injection of AF-353 into the carotid body in situ. The residual depressor response in the presence of AF-219 that remains after carotid body ablation suggests a contribution from other sensory afferents, in which P2X3 receptors have become active. Such sensory afferents could include glomus tissue in the thorax and abdomen, but this remains to be tested. Mechanistically, the decrease in sympathetic activity induced by P2X3-receptor antagonism included a reduction in its modulation by respiration, particularly by the expiratory component of respiration. It is this component that is upregulated in numerous models of hypertension 56, 57 , a finding that supports the importance of the central respiratory generator as a major driver of autonomic imbalance in hypertension 57 . P2X3-receptor antagonism also improved the spontaneous cardiac baroreceptor reflex, which possibly reflects the removal of the inhibitory influence of the carotid body on the carotid sinus baroreceptor reflex, as reported previously in both SH rats 20 and individuals with hypertension 58 . This improved baroreflex gain might contribute to the sympatho-inhibition and antihypertensive effects of P2X3-receptor antagonism in the SH rat.
The potential clinical importance of the upregulation of P2X3-receptor expression in the carotid body and petrosal neurons to pathology should not be underestimated. Administration of a P2X3-receptor antagonist might be able to attenuate aberrant signaling without affecting physiological function. Our data support this concept; carotid body tonic drive and hyperreflexia were abated by P2X3-receptor antagonism in hypertensive rats, yet the system remained physiologically responsive to stimulation, akin to control animals. These results are entirely consistent with the results of a recent human trial to treat chronic pathological cough, in which coughing was abated but physiological and protective cough reflexes did not seem to be altered by P2X3 receptor antagonism 29 .
Peripheral chemoreception has both regulatory and protectivereflex functions 59 . Thus, an important consideration for the clinical use of a P2X3 antagonist such as AF-219 is whether it can abolish pathological signaling while preserving normal carotid body function. An issue for the clinical use of P2X3 antagonists might be the known adverse effects of P2X3 antagonism on taste perception 29 , but appropriate dosing should be able to negate this.
Over the past 20 years, there has been a dearth of novel antihypertensive therapeutics 7 . We speculate that P2X3-receptor antagonism might be most efficacious in a subpopulation of humans with uncontrolled hypertension, demonstrable aberrant carotid body activity and an overactive sympathetic nervous system. The presence of P2X3 receptors in the carotid body of hypertensive humans, the release of ATP from human glomus cells in response to hypoxia 35 and the ability of dopamine infusion to select those individuals with aberrant carotid body discharge support the undertaking of a clinical trial to test the antihypertensive effects of P2X3 antagonism.
METHODS
Methods and any associated references are available in the online version of the paper. 
